Larkhall mother applauds funding for new life-saving leukaemia treatment – Daily Record
A mother of three from Larkhall, who has navigated the challenges of life-saving leukaemia treatment, is embracing new funding for research that could unveil improved therapies for individuals grappling with this form of blood cancer. In August 2017, Peppie Scobbie, aged 53, experienced symptoms such as fatigue, persistent infections, and unexplained bruising, which turned out to be indicators of acute myeloid leukaemia (AML), a highly aggressive type of leukaemia. Following the diagnosis, Peppie underwent rounds of chemotherapy but faced complications like sepsis and pneumonia, leading to an intensive care stint in a medically induced coma.
After battling through subsequent rounds of chemotherapy, Peppie eventually achieved remission and underwent two stem cell transplants. However, the last transplant resulted in a prolonged hospitalisation due to ‘Graft vs Host’ disease, where the body’s white blood cells attack its own tissues. Several years on, Peppie still grapples with the aftermath of treatment, such as mouth and gut damage, bone deterioration necessitating knee replacements, and persistent pain. Regular blood tests are part of her routine to monitor her health, with a forthcoming hip replacement on the horizon.
Peppie expressed, “I was speechless upon my diagnosis, despite experiencing all the classic symptoms of leukaemia. The past few years have been challenging undergoing and continuing treatment. It’s mentally taxing, and I have moments of asking, ‘why me?’ but I strive to maintain a positive outlook.”
She added, “No one should endure what I have. I hope the new funding from Leukaemia UK aids in identifying urgently needed treatment options to enable individuals diagnosed with leukaemia to live well.” Leukaemia UK, a research and advocacy charity, awards the John Goldman fellowships to promising early career researchers annually. Each fellow receives £150,000 in funding and mentorship to translate crucial discoveries from the laboratory to clinical applications. These fellowships honour Professor John Goldman, a renowned hematologist, oncologist, and a founding figure of Leuka, the precursor to Leukaemia UK.
Among this year’s fellows at the University of Cambridge, two will focus on AML research, aiming to enhance treatment options for patients like Peppie. Dr Cecile Lopez will study the ERG protein’s potential role in leukaemia development, while Dr Eliza Yankova will explore the METTL1 gene’s impact on cancer progression, including AML.
Fiona Hazell, Chief Executive of Leukaemia UK, remarked, “We are thrilled to support these innovative projects that concentrate on enhancing outcomes for aggressive blood cancers. Spearheaded by pioneering young researchers, these valuable insights could pave the way for improved, targeted treatments crucial for transforming patient outcomes.”
In summary, Peppie Scobbie’s journey exemplifies the resilience required to combat leukaemia, while the new research funding from Leukaemia UK holds promise for pioneering treatments in the future, offering hope to those impacted by this life-altering disease.